These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14570304)

  • 1. Dissolution and absorption modeling: model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption.
    Johnson KC
    Drug Dev Ind Pharm; 2003 Sep; 29(8):833-42. PubMed ID: 14570304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering nifedipine in vivo delivery from modified release dosage forms: Identification of food effect.
    Ilić M; Kovačević I; Parojčić J
    Acta Pharm; 2015 Dec; 65(4):427-41. PubMed ID: 26677899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation.
    Tanaka N; Imai K; Okimoto K; Ueda S; Tokunaga Y; Ibuki R; Higaki K; Kimura T
    J Control Release; 2006 May; 112(1):51-6. PubMed ID: 16545477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine.
    Gajendran J; Krämer J; Shah VP; Langguth P; Polli J; Mehta M; Groot DW; Cristofoletti R; Abrahamsson B; Dressman JB
    J Pharm Sci; 2015 Oct; 104(10):3289-98. PubMed ID: 26149619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation.
    Wagner C; Thelen K; Willmann S; Selen A; Dressman JB
    J Pharm Sci; 2013 Sep; 102(9):3205-19. PubMed ID: 23696038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced dissolution and oral bioavailability of nifedipine by spontaneous emulsifying powders: effect of solid carriers and dietary state.
    Weerapol Y; Limmatvapirat S; Jansakul C; Takeuchi H; Sriamornsak P
    Eur J Pharm Biopharm; 2015 Apr; 91():25-34. PubMed ID: 25615879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of nifedipine-loaded coated gelatin microcapsule as a long acting oral delivery.
    Li DX; Kim JO; Oh DH; Lee WS; Hong MJ; Kang JY; Choi JS; Woo JS; Yong CS; Choi HG
    Arch Pharm Res; 2009 Jan; 32(1):127-32. PubMed ID: 19183885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine.
    Chung M; Reitberg DP; Gaffney M; Singleton W
    Am J Med; 1987 Dec; 83(6B):10-4. PubMed ID: 3503594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs.
    Yu LX; Ellison CD; Conner DP; Lesko LJ; Hussain AS
    AAPS PharmSci; 2001; 3(3):E24. PubMed ID: 11741275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.
    Franek F; Jarlfors A; Larsen F; Holm P; Steffansen B
    Eur J Pharm Sci; 2015 Sep; 77():303-13. PubMed ID: 26091569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.
    Grundy JS; Foster RT
    Clin Pharmacokinet; 1996 Jan; 30(1):28-51. PubMed ID: 8846626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the influence of cyclodextrins on oral absorption of low solubility drugs: II. Experimental validation.
    Gamsiz ED; Miller L; Thombre AG; Ahmed I; Carrier RL
    Biotechnol Bioeng; 2010 Feb; 105(2):421-30. PubMed ID: 19725043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses.
    Garbacz G; Golke B; Wedemeyer RS; Axell M; Söderlind E; Abrahamsson B; Weitschies W
    Eur J Pharm Sci; 2009 Sep; 38(2):147-55. PubMed ID: 19591927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of nifedipine controlled release tablets prepared using mucoadhesive swellable polymer.
    Felician WA; Ghaly ES
    Pharm Dev Technol; 2011 Oct; 16(5):536-41. PubMed ID: 20954856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting the release of nifedipine from a swellable elementary osmotic pump.
    Nokhodchi A; Momin MN; Shokri J; Shahsavari M; Rashidi PA
    Drug Deliv; 2008 Jan; 15(1):43-8. PubMed ID: 18197523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off.
    Beig A; Miller JM; Dahan A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1293-9. PubMed ID: 23770429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
    Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
    Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations.
    Corrigan OI
    Adv Exp Med Biol; 1997; 423():111-28. PubMed ID: 9269487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Dissolution in the Lower Intestine and Its Impact on the Absorption Process of High Dose Low Solubility Drugs.
    Georgaka D; Butler J; Kesisoglou F; Reppas C; Vertzoni M
    Mol Pharm; 2017 Dec; 14(12):4181-4191. PubMed ID: 28366005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.